Extended Data Fig. 1: Clinical outcomes in the biomarker-evaluable population (BEP) are representative of those in the intention-to-treat (ITT) population in GO30140 and IMbrave150 clinical trials.

Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS) in patients in the ITT and BEP of a, GO30140 group A & F (A n = 90, F n = 91 biologically independent subjects) or b, IMbrave150 (n = 119 biologically independent subjects). Stratified hazard ratios and two-sided log-likelihood P values for progression or death are reported. 95% confidence intervals are indicated in parentheses. A table comparing independent review facility–assessed objective response rate in the BEP and ITT population in GO30140 group A is included in (a). The variables used for stratification in the Cox model for IMBrave 150 (b) were geographic region (Asia [excluding Japan] vs the rest of the world), α-fetoprotein categorical level at baseline (<400 ng per milliliter vs ≥400 ng per milliliter), and the presence of either macrovascular invasion or extrahepatic spread (vs the d of both). Tick marks indicate censored data. Numbers in parentheses indicate CIs. Atezo, atezolizumab; Bev, bevacizumab; CR, complete response; HR, hazard ratio; PD, progressive disease; PR, partial response; SD, stable disease.